Biogen brags of Phase III data for would-be Aubagio rival oral MS drug

Share this article:
A study published in the New England Journal of Medicine indicates that Biogen Idec's experimental MS drug, BG-12 is on track to make an impression. The study said patients taking the oral medication had a significantly lower annual relapse rate at two years when taking the drug two or three times a day, compared with placebo. The study did not show the drug had any significant impact on slowing disease progression.

Thursday's news brings the drug one step closer to its built-in fan base. It also comes a week after the FDA approved Sanofi's oral contender, Aubagio (teriflunomide). Phase III trials of Sanofi's therapy reduced the relapse rate among MS patients by about 30%. Industry watchers told MM&M at the time that the approval expanded patient options, but it was going to have a longer acceptance curve among physicians than BG-12, which has cultivated a level of pre-approval confidence with its safety and efficacy profile.

Ben Weintraub, director of research at the health analytics firm InThought, told MM&M at the time of Sanofi's Augbagio approval that this will translate into doctor preference for the Biogen Idec drug over rivals like Aubagio or Tysabri for second-line use when interferon and Copaxone fail.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...